PT  - JOURNAL ARTICLE
AU  - Redd, Andrew D
AU  - Nardin, Alessandra
AU  - Kared, Hassen
AU  - Bloch, Evan M
AU  - Pekosz, Andrew
AU  - Laeyendecker, Oliver
AU  - Abel, Brian
AU  - Fehlings, Michael
AU  - Quinn, Thomas C
AU  - Tobian, Aaron AR
TI  - CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
AID  - 10.1101/2021.02.11.21251585
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.11.21251585
4099  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251585.short
4100  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251585.full
AB  - This study examined whether CD8+ T-cell responses from COVID-19 convalescent individuals(n=30) potentially maintain recognition of the major SARS-CoV-2 variants. Out of 45 mutations assessed, only one from the B.1.351 Spike overlapped with a low-prevalence CD8+ epitope, suggesting that virtually all anti-SARS-CoV-2 CD8+ T-cell responses should recognize these newly described variants.Competing Interest StatementH.K., B.A., A.N., and M.F. are shareholders and/or employees of ImmunoScape Pte Ltd. A.N. is a Board Director of ImmunoScape Pte Ltd.Funding StatementThis work was supported in part by National Institute of Allergy and Infectious Diseases (NIAID) R01AI120938, R01AI120938S1 and R01AI128779 (A.A.R.T); the Division of Intramural Research, NIAID, NIH (O.L., A.R., T.Q.); and National Heart Lung and Blood Institute 1K23HL151826-01 (E.M.B).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Johns Hopkins Institutional Review Board, and all participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this analysis is available in a previous publication "SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals" https://www.jci.org/articles/view/145476